Ivan Rich, PhD, Founder and CEO of HemoGenix(R), said that, "It has been a pleasure working with ORF. Their response and products have been exceptional. Incorporating these growth factors and cytokines in our HALO(R) Platform products is extremely important for our quality control and potency assays, because we can now use biorisk- and contaminant-free products that provide far greater clinical relevance for the results that are obtained with our kits and services."
Bjorn Orvar, PhD, Co-founder and CEO of ORF Genetics, said that, "ORF Genetics ISOkine(TM) growth factors produced in our Orfeus(TM) plant-based production system are not only a novel approach for producing growth factors, but also a much-needed option for endotoxin-free, and animal- and serum-free components, for cell culture and medical research. HemoGenix(R) is a global leader of developing kits and assays for high throughput and validated cell- based assays for the detection and prediction of hemotoxicity, and we are very pleased to collaborate with HemoGenix(R) for the incorporation of our ISOkine(TM) growth factors and cytokines in its HALO(R) Hemotoxicity Assay Kits and Contract Research Services using the HALO(R) platform."
About HemoGenix(R), Inc
HemoGenix(R) was the first company in the world to provide high throughput
and predictive cell-based in vitro assays to detect human hemotoxicity
(toxicity to the blood-forming system). The HALO(R) Platform and other
proprietary assays (LUMENESC(TM) and LumiSTEM(TM)) for different cell systems
share the same ATP-based, in vitro bioluminescence technology. This allows
biological responses to virtually any agent to be directly compared with each
other across cell systems from different species simultaneously. Since its
founding in 2000, HemoGenix(R) has developed its own portfolio of patented
|SOURCE HemoGenix, Inc|
Copyright©2008 PR Newswire.
All rights reserved